Acacia Diversified Holdings, Inc.

Acacia Diversified Holdings, Inc. engages in the extraction and processing of high-CBD/low-THC content medical grade hemp oils from medical hemp plants in the United States. The company is also involved in the research and development of botanicals endocannabinoid nutraceuticals product line; and retail and wholesale distribution of medicinal hemp products and dietary supplements. In addition, it offers consumer products under the EUFLORIA brand name for the distribution channels. The company was formerly known as Acacia Automotive, Inc. and changed its name to Acacia Diversified Holdings, Inc. in October 2012. Acacia Diversified Holdings, Inc. was incorporated in 1984 and is based in Clearwater, Florida.

Acacia Diversified Holdings, Inc. trades as ACCA on OTC. The company is classified in Healthcare / Drug Manufacturers - Specialty & Generic and reports in USD.

The current profile places the business in Drug Manufacturers - Specialty & Generic. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Acacia Diversified Holdings, Inc. can be compared against peers such as American Bio Medica Corporation, Allied Healthcare Products, Inc., Gene Biotherapeutics, Inc., American CryoStem Corporation, DermTech, Inc., E-Qure Corp..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $5,428, beta of -0.55, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

ACCA currently shows total debt of N/A and beta of -0.55. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.acaciadiversifiedholdings.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.